Nuveen Asset Management LLC Has $951,000 Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Nuveen Asset Management LLC trimmed its stake in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 32.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,237 shares of the company's stock after selling 60,020 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.25% of Cryoport worth $951,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after buying an additional 1,764 shares in the last quarter. Olympiad Research LP bought a new stake in Cryoport during the 4th quarter worth $103,000. Heritage Investors Management Corp acquired a new position in Cryoport in the 4th quarter worth about $122,000. AlphaQuest LLC raised its position in Cryoport by 81.3% in the fourth quarter. AlphaQuest LLC now owns 52,714 shares of the company's stock valued at $410,000 after purchasing an additional 23,631 shares during the last quarter. Finally, Thrivent Financial for Lutherans bought a new position in Cryoport in the fourth quarter valued at about $299,000. Institutional investors own 92.90% of the company's stock.

Analysts Set New Price Targets

CYRX has been the topic of several research reports. Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of Cryoport in a report on Thursday, May 8th. UBS Group boosted their target price on shares of Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Roth Mkm reaffirmed a "buy" rating and set a $15.00 price target on shares of Cryoport in a research note on Tuesday, April 1st. Morgan Stanley cut their price target on shares of Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Finally, Guggenheim restated a "buy" rating and issued a $10.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Cryoport has an average rating of "Moderate Buy" and an average target price of $11.00.

Insider Transactions at Cryoport

In related news, Director Robert J. Hariri sold 12,500 shares of the firm's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total transaction of $76,250.00. Following the completion of the sale, the director now owns 8,061 shares of the company's stock, valued at $49,172.10. This trade represents a 60.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jerrell Shelton sold 4,620 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,330 shares of company stock valued at $194,603. Corporate insiders own 10.00% of the company's stock.

Cryoport Trading Up 5.1%

Shares of NASDAQ CYRX traded up $0.34 during midday trading on Friday, reaching $7.00. The stock had a trading volume of 622,076 shares, compared to its average volume of 537,882. The company's 50 day moving average price is $5.91 and its 200 day moving average price is $6.72. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a twelve month low of $4.58 and a twelve month high of $11.64. The firm has a market cap of $350.96 million, a price-to-earnings ratio of -2.07 and a beta of 1.92.

Cryoport (NASDAQ:CYRX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. As a group, sell-side analysts expect that Cryoport, Inc. will post -0.99 EPS for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.